Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 12/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18570634 | 1.00 | GRIK1 (0.52) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL10187367 | 0.83 | GRIK1 (0.52) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL2491511 | 0.81 | GRIK1 (0.48) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL15242548 | 0.81 | KDM4E (0.39) | GRIK1GRIK2GRIA4GRIK3GRIK5 | |
| SCHEMBL8244 | 0.80 | — | — | |
| SCHEMBL6027700 | 0.80 | — | — | |
| SCHEMBL6028073 | 0.80 | — | — | |
| Aspartic Acid SCHEMBL28048942 | 0.80 | GRIK1 (0.50) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL5050477 | 0.78 | SLC1A1 (0.53) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL826657 | 0.78 | GSR (0.56) | GRIK1GRIK2GRM1GRM2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| EP-4389145-A2 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-3225248-B1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | AMBRX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-2399893-A2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Ambrx, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011087810-A1 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011079293-A1 | TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND POLYPEPTIDES AND THEIR USES | AMBRX, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-2284191-A2 | Process for the preparation of hGH | Ambrx, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010006214-A1 | FGF-21 NEUTRALIZING ANTIBODIES AND THEIR USES | AMBRX, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009117622-A2 | MODIFIED FGF-23 POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009067636-A2 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | INSERM (INSTITUT NATIONAL DE LA SANT'E ET DE LA RECHERCHE MEDICALE (FR) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | GRIK1 4498/4885SLC7A5 2199/4885GRIK2 1917/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GRIK1 4775/4885SLC7A5 264/4885GRIK2 4675/4885 |
| US-20070161807-A1 | Method for manufacturing optically pure coumaryl amino acids and the novel coumaryl aminoacids thus obtained | CRYAA, BCAT2, BCAT1 | GRIK1 4191/4885SLC7A5 180/4885GRIK2 3945/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GRIK1 771/4885SLC7A5 2905/4885GRIK2 882/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | GRIK1 1610/4885SLC7A5 2188/4885GRIK2 1519/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GRIK1 4755/4885SLC7A5 221/4885GRIK2 4620/4885 |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GRIK1 2141/4885SLC7A5 4040/4885GRIK2 2045/4885 |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | CSF3R, GMFG, HDGF | GRIK1 1610/4885SLC7A5 2188/4885GRIK2 1519/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | GRIK1 1657/4885SLC7A5 2122/4885GRIK2 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.